ArticleJournal of addiction medicine
Anhedonia and Substance Use Disorders by Type, Severity, and With Mental Health Disorders.
Article in Journal of addiction medicine. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 17 citations in OpenAlex.
- Phenotypic Clustering of Addictions Reveals Impulsivity Links to Internalizing Disorders: A Network Analysis.Alpha psychiatry · 2026Article
- Dimensional Anhedonia Rating Scale (DARS) Turkish Version: Examination of Psychometric Properties in Depressed and Ultra-High Risk/Psychotic Adolescents.The Psychiatric quarterly · 2026Article
- Interformat equivalence between paper and electronic administrations of the self-assessment anhedonia scale in a substance use disorder clinical sample.Frontiers in psychology · 2026Article
- Affect-laden risk profiles derived from two days of EMA predict substance use and quality of life three- and six-months after SUD treatment.Journal of substance use and addiction treatment · 2025Article
- Anhedonia is associated with higher functional connectivity between the nucleus accumbens and paraventricular nucleus of thalamus.Journal of affective disorders · 2024Article
- Inclusion of Individuals With Lived Experiences in the Development of a Digital Intervention for Co-Occurring Depression and Cannabis Use: Mixed Methods Investigation.JMIR formative research · 2024Article
- From mood to use: Using ecological momentary assessments to examine how anhedonia and depressed mood impact cannabis use in a depressed sample.Psychiatry research · 2024Article
- Review
- Exploring the harm reduction paradigm: the role of Board-Certified Psychiatric Pharmacists.The mental health clinician · 2024Article
- Beta activity in human anterior cingulate cortex mediates reward biases.Nature communications · 2024Article
- Deficits in consummatory reward relate to severity of cocaine use.Drug and alcohol dependence · 2023Article
- Variability in intensively assessed mood: Systematic sources and factor structure in outpatients with opioid use disorder.Psychological assessment · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
Abstract
objectivesAnhedonia can accompany substance use disorders (SUDs); its severity may vary by substance type, severity of SUD symptoms, or psychiatric comorbidity. The goal of this study was to clarify the contribution of each.
methodsData were from participants aged 18 to 65 years in the National Epidemiologic Survey on Alcohol and Related Conditions III (n = 30,999; 51% women), a cross-sectional, nationally representative sample reporting lifetime DSM-5 symptoms and lifetime anhedonia. We used logistic regression to test how anhedonia was associated with specific SUDs and psychiatric disorders in respondents with one lifetime diagnosis. We used latent class analysis to assess the association of anhedonia with patterns of comorbidity in all respondents.
resultsOpioid use disorder (OUD) had the greatest odds of anhedonia relative to other SUDs (ORs [95% CIs]): mild alcohol use disorder (AUD) ( 3.33 [1.74, 6.38]), moderate/severe AUD ( 2.73 [1.41, 5.30]), and cannabis use disorder ( 3.21 [1.43, 7.19]), though not significantly greater than stimulant use disorder ( 2.44 [.88, 6.73]). Anhedonia was more likely in mood disorders and posttraumatic stress disorder (PTSD) than in any SUD, except for PTSD versus OUD (OR [95% CIs] = .98 [.47, 2.02]). In latent class analysis analyses, the poly disorder class, which included SUDs and other diagnoses, had greater odds of anhedonia than the Poly SUD (ORs [95% CIs] = 1.62 [1.25, 2.09] and AUD 2.89 [2.40, 3.48]) classes.
conclusionsPeople with OUD or a lifetime history of mood disorder or PTSD may be most likely to present to SUD treatment with anhedonia.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.